Mark Socinski, MD | Authors

February 01, 2023

Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.

February 01, 2023

Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.

February 01, 2023

Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.

February 01, 2023

Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.

February 01, 2023

Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.

January 31, 2023

Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.